- Home
- GWRS vs FHTX Comparison
GWRS vs FHTX Comparison
Compare GWRS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- FHTX
- Stock Information
- Founded
- GWRS 2003
- FHTX 2015
- Country
- GWRS United States
- FHTX United States
- Employees
- GWRS N/A
- FHTX N/A
- Industry
- GWRS Water Supply
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- GWRS Utilities
- FHTX Health Care
- Exchange
- GWRS Nasdaq
- FHTX Nasdaq
- Market Cap
- GWRS 288.9M
- FHTX 517.9M
- IPO Year
- GWRS 2010
- FHTX 2020
- Fundamental
- Price
- GWRS $12.89
- FHTX $7.23
- Analyst Decision
- GWRS
- FHTX Strong Buy
- Analyst Count
- GWRS 0
- FHTX 5
- Target Price
- GWRS N/A
- FHTX $16.00
- AVG Volume (30 Days)
- GWRS 18.8K
- FHTX 133.0K
- Earning Date
- GWRS 11-06-2024
- FHTX 10-31-2024
- Dividend Yield
- GWRS 2.33%
- FHTX N/A
- EPS Growth
- GWRS N/A
- FHTX N/A
- EPS
- GWRS 0.26
- FHTX N/A
- Revenue
- GWRS $52,020,000.00
- FHTX $35,185,000.00
- Revenue This Year
- GWRS $2.72
- FHTX N/A
- Revenue Next Year
- GWRS $3.56
- FHTX $15.40
- P/E Ratio
- GWRS $50.29
- FHTX N/A
- Revenue Growth
- GWRS 5.90
- FHTX 61.95
- 52 Week Low
- GWRS $9.34
- FHTX $2.70
- 52 Week High
- GWRS $13.42
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- GWRS 56.28
- FHTX 41.45
- Support Level
- GWRS $12.75
- FHTX $7.24
- Resistance Level
- GWRS $13.30
- FHTX $8.35
- Average True Range (ATR)
- GWRS 0.28
- FHTX 0.57
- MACD
- GWRS 0.09
- FHTX -0.08
- Stochastic Oscillator
- GWRS 68.46
- FHTX 16.02
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operate within the State of Arizona.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.